She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

Regarding the key secondary endpoints, Emmett reported that deterioration-free survival at 12 months favored the combination over enzalutamide for both physical function (median 10.6 vs 3.4 months ...